Nabla Taps Commercial Veteran to Scale Its AI Healthcare Empire

NEW YORK, NY – July 21, 2026 – In a move signaling a strategic shift from pure innovation to aggressive market domination, clinical AI leader Nabla has appointed Brian Manning as its new Chief Executive Officer. The appointment is more than a standard leadership change; it represents a calculated fusion of proven commercial muscle with frontier AI research, a combination the company is betting will cement its position as the foundational intelligence layer for modern healthcare.

While Manning steps in to accelerate growth, co-founder Alex LeBrun transitions from CEO to the dual role of Executive Chairman and Chief AI Officer. This shuffle allows LeBrun to focus on long-term strategy and deepen the company’s exclusive partnership with AMI Labs, the frontier AI research firm he co-founded with Turing Award winner Yann LeCun. The message is clear: while Manning builds the commercial engine, LeBrun is designing the next-generation fuel.

The Commercial Growth Engine

Brian Manning is, by all accounts, a scaler. His resume is a testament to his ability to transform promising technology companies into commercial powerhouses. He joins Nabla from Bamboo Health, where as President and Chief Revenue Officer, he was instrumental in scaling the company to over $140 million in annual recurring revenue. Before that, he built the entire go-to-market organization at PatientPing, guiding it from its early days to a successful acquisition. His career also includes a pivotal role in establishing the enterprise sales division at Zocdoc during its own hyper-growth phase.

This track record is precisely what Nabla needs at this juncture. The company has already achieved significant traction, with its AI assistant deployed across 190 healthcare organizations and used by over 100,000 clinicians. With a footprint that touches 40 million patient encounters annually, Nabla has proven its product’s value. The challenge now is not to prove that it works, but to make it ubiquitous.

"Brian has a rare ability to build organizations that pair commercial excellence with long-term vision," said Alex LeBrun in the company’s announcement. This sentiment underscores the strategy: leveraging Manning's expertise to capitalize on the strong foundation Nabla has already built. His mandate is to take a widely adopted product and turn it into an industry standard.

A Crowded Field with a Differentiating Vision

Nabla operates in the increasingly competitive ambient AI market, where solutions aim to alleviate the crushing administrative burden on clinicians. Competitors like Nuance/Microsoft's DAX Copilot and Abridge AI, which has earned accolades for its deep integration with the Epic EHR system, are formidable players. However, Nabla has carved out a strategic position that Manning is now poised to exploit.

Where some competitors have focused on deep integration with a single EHR, Nabla has pursued a strategy of broad compatibility, integrating with over 20 major EHRs, including Epic and Oracle Cerner. This makes it an attractive solution for large, complex health systems that often operate with a mixed IT environment. Furthermore, its support for over 35 languages gives it a distinct advantage in diverse clinical settings and global markets.

This strategy is in service of a larger vision the company calls 'Contextual Clinical Intelligence.' Nabla aims to move beyond simply transcribing conversations into clinical notes. The goal is to create a unified AI layer that connects intelligence across the entire care journey—from pre-visit preparation and in-encounter support to post-visit follow-up and revenue cycle management. It’s a shift from being a helpful tool to becoming the intelligent, connective tissue of clinical operations.

From Ambient Scribe to Agentic AI

Nabla’s most significant differentiator may be its access to a future that other companies can only read about. The exclusive partnership with AMI Labs provides a direct pipeline to what many believe is the next paradigm in artificial intelligence: world models. Co-founded by LeBrun and AI pioneer Yann LeCun, AMI Labs recently raised over $1.2 billion to build these advanced systems.

Unlike today's large language models (LLMs), which excel at generating probabilistic text, world models are designed for simulation-based reasoning. They build an internal, abstract understanding of a system, allowing them to reason about cause and effect, plan multi-step actions, and run 'what-if' scenarios before acting. For the high-stakes environment of healthcare, this capability is transformative. It’s the difference between an AI that can write a good note and an AI that can understand the clinical context well enough to help coordinate a complex care plan.

Nabla plans to leverage this technology to build what it calls "Agentic AI." This next-generation assistant is envisioned to autonomously execute complex workflows, such as coordinating referrals, navigating labyrinthine scheduling systems, assessing insurance constraints, and initiating pre-visit lab orders. LeBrun’s shift to Chief AI Officer is a strategic move to personally oversee the integration of this groundbreaking research into Nabla’s product roadmap, ensuring the company stays at the bleeding edge of what’s possible.

The Real-World Impact on the Front Lines

While the vision for agentic AI is futuristic, Nabla’s current impact is tangible and measurable today. For the clinicians on the front lines, the platform is already a game-changer. Data from deployments shows a direct correlation between Nabla's use and a reduction in clinician burnout, a crisis plaguing the healthcare industry. University of Iowa Health Care reported a 26% sustained reduction in burnout, while Denver Health saw a 30% decrease in burnout scores among users.

These improvements are driven by concrete time savings. Clinicians report saving hours on charting each week, with some studies showing users spend 13-16 fewer minutes per day on EHR tasks. This reclaimed time is being reinvested into patient care, improving the quality of interactions and strengthening the patient-provider relationship. The results are reflected in adoption metrics: pilots have seen 100% clinician adoption, and post-pilot retention rates are as high as 80%.

With major health systems like CVS Health and UCLA Health already on its client roster, Nabla has demonstrated its ability to deliver value at scale. The appointment of Brian Manning is a clear signal that the company is ready to press its advantage, combining its profound technological depth with the commercial velocity needed to redefine how healthcare is documented, managed, and delivered.